Accenture plc (ACN)vsAmgen Inc (AMGN)
ACN
Accenture plc
$180.42
+0.13%
TECHNOLOGY · Cap: $111.04B
AMGN
Amgen Inc
$331.70
+0.79%
HEALTHCARE · Cap: $177.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Accenture plc generates 94% more annual revenue ($72.11B vs $37.22B). AMGN leads profitability with a 21.0% profit margin vs 10.6%. ACN appears more attractively valued with a PEG of 1.27. AMGN earns a higher WallStSmart Score of 62/100 (C+).
ACN
Buy62
out of 100
Grade: C+
AMGN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+35.7%
Fair Value
$280.38
Current Price
$180.42
$99.96 discount
Margin of Safety
-2.2%
Fair Value
$321.89
Current Price
$331.70
$9.81 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Every $100 of equity generates 25 in profit
Attractively priced relative to earnings
Generating 3.7B in free cash flow
Every $100 of equity generates 101 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Areas to Watch
4.0% earnings growth
Weak financial health signals
Expensive relative to growth rate
Trading at 19.5x book value
4.4% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : ACN
The strongest argument for ACN centers on Market Cap, Return on Equity, P/E Ratio. PEG of 1.27 suggests the stock is reasonably priced for its growth.
Bull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bear Case : ACN
The primary concerns for ACN are EPS Growth, Piotroski F-Score.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.
Key Dynamics to Monitor
ACN profiles as a value stock while AMGN is a mature play — different risk/reward profiles.
ACN carries more volatility with a beta of 1.07 — expect wider price swings.
ACN is growing revenue faster at 8.3% — sustainability is the question.
ACN generates stronger free cash flow (3.7B), providing more financial flexibility.
Bottom Line
ACN scores higher overall (62/100 vs 62/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Accenture plc
TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA
Accenture plc is an Irish-domiciled multinational company that provides consulting and processing services. It has been incorporated in Dublin, Ireland since 2009.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Compare with Other INFORMATION TECHNOLOGY SERVICES Stocks
Want to dig deeper into these stocks?